NeuroVive Pharmaceutical AB Year End Report January - December 2019
Important events in 2019 KL1333 · NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study · NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study · NeuroVive completes recruitment of healthy volunteers in the second part of its ongoing KL1333 clinical Phase Ia/b study NV354 · NeuroVive initiates NV354 preclinical safety studies and scales up compound production NeuroSTAT · NeuroVive’s IND for clinical development of NeuroSTAT approved by FDA · NeuroSTAT receives Fast Track designation from the US Food and